On May 06, 2014, Infinity Pharmaceuticals Inc. (NASDAQ:INFI), announced its first quarter 2014 financial results and ongoing progress with IPI-145, the company’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Infinity Pharmaceuticals Inc. (NASDAQ:INFI), weekly performance is 4.01%. On last trading day company shares ended up $9.85. Analysts mean target price for the company is $18.67. Infinity Pharmaceuticals Inc. (NASDAQ:INFI), distance from 50-day simple moving average (SMA50) is -15.26%.
Amicus Therapeutics, Inc. (NASDAQ:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, announced financial results for the first quarter ended March 31, 2014. The Company also provided program updates and reiterated full-year 2014 operating expense guidance. Cash, cash equivalents, and marketable securities totaled $71.6 million at March 31, 2014 compared to $82.0 million at December 31, 2013. Total operating expenses decreased to $16.1 million compared to $17.3 million for the first quarter 2013 due to decreases in personnel and contract research costs. Net cash spend was $10.4 million, compared to $14.4 million for the first quarter 2013. Net loss was $15.9 million, or $0.25 per share, compared to a net loss of $17.5 million, or $0.35 per share, for the first quarter 2013. Amicus Therapeutics, Inc. (NASDAQ:FOLD), advanced 7.04% in last trading session and ended the day on $2.28. RRST, return on assets is -64.10%. Amicus Therapeutics, Inc. (NASDAQ:FOLD), quarterly performance is -14.29%.
On May 07, 2014, ArQule, Inc. (NASDAQ:ARQL), reported Q1 EPS of ($0.11), in-line with the analyst estimate of ($0.11). At March 31, 2014, the Company had a total of $85,758,000 in cash, equivalents and marketable securities. ArQule, Inc. (NASDAQ:ARQL), shares moved up 7.14% in last trading session and was closed at $1.50, while trading in range of $ 1.38 – 1.51. ArQule, Inc. (NASDAQ:ARQL), year to date (YTD) performance is -30.23%.
Prothena Corporation PLC (NASDAQ:PRTA), CEO Dale B. Schenk acquired 8,000 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average cost of $20.79 per share, with a total value of $166,320.00. Following the transaction, the chief executive officer now directly owns 8,161 shares in the company, valued at approximately $169,667. Prothena Corporation PLC (NASDAQ:PRTA), ended the last trading day at $20.86. Company weekly volatility is calculated as 10.05% and price to cash ratio as 2.59. Prothena Corporation PLC (NASDAQ:PRTA), showed a negative weekly performance of 3.83%.